Bli medlem
Bli medlem

Du är här


MDxHealth (R): MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland

Further broadens reach of SelectMDx(TM) for Prostate Cancer in Europe

- October 19, 2016 -MDxHealthSA (Euronext: MDXH.BR) a multinational healthcare
company that provides actionable epigenetic information to personalize the
diagnosis and treatment of urologic cancers, today announced an agreement
with the HIFU CLINIC Prostate Cancer Center (HIFU CLINIC) for distribution of
its SelectMDx(TM) for Prostate Cancer liquid biopsy assay throughout Poland.
HIFU CLINIC will be the second distributor of SelectMDx in Poland.

Marek Filipek, MD, PhD, HIFU CLINIC Medical Director, stated:
"Bringing the SelectMDx assay to the Polish market is a turning point in
providing an advanced prostate cancer diagnostic decision tool that is both
sensitive and specific to Polish Patients and their Physicians. The
well-validated, non-invasive SelectMDx liquid biopsy test stands out in a
growing field of yet unproven tools. Early identification of patients at risk
for clinically significant prostate cancer is the key to accurate patient
selection for prostate biopsy, with likely benefit to long term clinical

"We are very pleased to announce our collaboration with HIFU CLINIC, whose
High Intensity Focused Ultrasound (HIFU) Clinic is the first and only Polish
center dedicated entirely to the comprehensive diagnostics and modern
treatment of prostate cancer. SelectMDx will perfectly complement HIFU
CLINIC's cutting edge diagnostic methods and procedures,"commented
Dr. Jan Groen, CEO of MDxHealth.
"We believe this key partnership will help us improve awareness and widen
access to SelectMDx throughout Poland."

About SelectMDx for Prostate Cancer

Of the nearly 2 million prostate biopsies performed each year, less than a
third find cancer. Most of these men could have avoided a painful and
invasive prostate biopsy procedure, with its associated complications and
costs. SelectMDx for Prostate Cancer is a proprietary urine-based, molecular
diagnostic test that offers a non-invasive 'liquid biopsy' method to assess a
man's risk for prostate cancer. SelectMDx helps identify men at increased
risk of harbouring aggressive, potentially lethal, prostate cancer who may
benefit most from a prostate biopsy and earlier detection. The test delivers
a negative predictive value (NPV) of 98% for clinically significant disease,
helping to reduce unnecessary MRI procedures and invasive prostate biopsies
by approximately 50%, thereby reducing healthcare costs.

About HIFU CLINIC Prostate Cancer Center

HIFU CLINIC Prostate Cancer Center is a unique private initiative dedicated to
bringing innovative medical care solutions in diagnostics and therapy to the
global patient base in cooperation with VEDI CLINIC Men's Health Clinic and
AMEDS Medical Center. The Group is an experienced regional leader in the
global medical tourism market in regard to, but not limited to, Men's Health.
HIFU CLINIC Prostate Cancer Center and VEDI CLINIC Men's Health Clinic serve
as providers of advanced diagnostic and treatment options to prostate cancer
and erectile dysfunction patients. For more information
visit:www.hifuclinic.euor follow us on Twitter

About MDxHealth

MDxHealth is a multinational healthcare company that provides actionable
molecular diagnostic information to personalize the diagnosis and treatment
of cancer. The company's tests are based on proprietary gene methylation
(epigenetic) and other molecular technologies and assist physicians with the
diagnosis of cancer, prognosis of recurrence risk, and prediction of response
to a specific therapy. For more information, visitmdxhealth.comand follow us
on Twitter

| For more information: Jonathan Birt, Chris Welsh, Hendrik Thys, Cameron Standage (PR&IR) |
| Consilium Strategic Communications |
| UK: +44 20 3709 5701 |
| US: +1 917 322 2571 (Rx Communications Group LLC) |
| |
| |
|Dr. Jan Groen, CEO |
|MDxHealth |
|US: +1 949 812 6979 |
|BE: +32 4 364 20 70 |
| |

| |
This press release contains forward-looking statements and estimates with
respect to the anticipated future performance of MDxHealth and the market in
which it operates. Such statements and estimates are based on assumptions and
assessments of known and unknown risks, uncertainties and other factors,
which were deemed reasonable but may not prove to be correct. Actual events
are difficult to predict, may depend upon factors that are beyond the
company's control, and may turn out to be materially different. MDxHealth
expressly disclaims any obligation to update any such forward-looking
statements in this release to reflect any change in its expectations with
regard thereto or any change in events, conditions or circumstances on which
any such statement is based unless required by law or regulation. This press
release does not constitute an offer or invitation for the sale or purchase
of securities or assets of MDxHealth in any jurisdiction. No securities of
MDxHealth may be offered or sold within the United States without
registration under the U.S. Securities Act of 1933, as amended, or in
compliance with an exemption therefrom, and in accordance with any applicable
U.S. securities laws.

NOTE: The MDxHealth logo, MDxHealth, ConfirmMDx, SelectMDx, AssureMDx and
PredictMDx are trademarks or registered trademarks of MDxHealth SA. All other
trademarks and service marks are the property of their respective owners.

To access the PDF version, click here


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: MDxHealth (R) via Globenewswire

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.